USA.Today25 Apr 2020 22:56
According to Stratistics MRC, the Global Non-Invasive Prenatal Testing market is accounted for $3.43 billion in 2018 and is expected to reach $11.62 billion by 2027 growing at a CAGR of 14.5% during the forecast period. Some of the key factors such as increasing programs related to awareness and growing maternal period are driving the market growth. However, lack of capable professionals is the restraining factor for the growth of the market.
Non-invasive prenatal testing is as well known as non-invasive parenteral screening, which is a hopeful genetic method of investigative a fetal cell free DNA there in the mothers blood serum for detecting general fetal aneuploidies. Its most important purpose is early recognition of genetic disorders such as trisomy 18 (Edward syndrome), trisomy 21 (Down syndrome), and monosomy X (Turner syndrome). It can as well distinguish the blood group and rhesus actor of the fetus.
By method, down syndrome (Trisomy 21) segment is likely to have a huge demand as it includes positive birth defects, education problems, and facial description. A child with Down syndrome can also contain heart defects and trouble with vision and hearing. According to the centres for illness control and prevention, it is the mostly general chromosomal situation diagnosed in United States. Every year, about six thousands babies born in the United States have Down syndrome. This way that Down syndrome occurs in about one out of each seven hundred babies. On the basis of geography, North America is going to have a lucrative growth during the forecast period due to favourable compensation policies and rise in the occurrence of genetic disorders. This will enlarge the acceptance and command for tests in this region.
Some of the key players in Non-Invasive Prenatal Testing Market include Illumina, Inc , Thermo Fisher Scientific, Inc, GE Healthcare, Perkinelmer Inc, Agilent Technologies, Inc, Beijing Genomics Institute, F. Hoffman-La Roche Ltd., and Laboratory Corporation of America Holdings, Natera, Inc......
......, Yourgene Health....
Quest Diagnostics, Sequenom, Bioarray S.L, Berry Genomics and LifeCodexx AG.